Medtronic (NYSE:MDT) touted data today from an economic analysis evaluating the use of professional continuous glucose monitoring in people with Type II diabetes.
Data from the study, which the company called the first of its kind, showed significant cost avoidance to the healthcare system when CGM was used during a therapy change or when used at least twice per year.
Published in the Journal of Medical Economics, the study included retrospective data from more than 5,600 people who used professional CGM in the U.S., based on health insurance medical claims, enrollment data and lab data.
Over a period of one year following the use of professional CGM, patients saw a net improvement of A1C of 0.4% and the total healthcare costs associated linked with these patients did not increase significantly compared to those who did not use professional CGM, according to data from the study.
The study also showed that if professional CGM was used when a patient was changing their diabetes therapy, the users spent $3,300 less than users in the control group.
“As a global leader in value-based healthcare, Medtronic is committed to ensuring that care delivered to people with diabetes, a global epidemic accounting for more than $500 billion annually of global healthcare costs, demonstrably improves patient outcomes while lowering the total cost of care,” Laura Stoltenberg, VP & GM of the Medtronic’s non-intensive diabetes therapies business, said in prepared remarks. “These findings suggest that professional CGM – like our iPro2 professional CGM – is not only an important therapy management tool that provides significant clinical benefits, but can also help alleviate the economic burden of Type II diabetes on the healthcare system.”
“Data from this study is compelling and adds to the growing body of clinical and now economic evidence demonstrating the significant benefits of professional CGM in patients with Type II diabetes,” Dr. Francine Kaufman, chief medical officer of Medtronic’s Diabetes Group, added. “As suggested in the American Association of Clinical Endocrinologists Consensus Statement on the use of professional CGM, it is a powerful tool to help get patients to their A1C target and reduce glycemic variability. These results also suggest that professional CGM can help reduce the escalating costs of Type II diabetes.”
